517 related articles for article (PubMed ID: 24755151)
1. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.
Hahn VS; Lenihan DJ; Ky B
J Am Heart Assoc; 2014 Apr; 3(2):e000665. PubMed ID: 24755151
[No Abstract] [Full Text] [Related]
2. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.
Padegimas A; Clasen S; Ky B
Trends Cardiovasc Med; 2020 Jan; 30(1):22-28. PubMed ID: 30745071
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Florido R; Smith KL; Cuomo KK; Russell SD
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
[No Abstract] [Full Text] [Related]
4. Anthracycline Chemotherapy and Cardiotoxicity.
McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline cardiotoxicity: from bench to bedside.
Gianni L; Herman EH; Lipshultz SE; Minotti G; Sarvazyan N; Sawyer DB
J Clin Oncol; 2008 Aug; 26(22):3777-84. PubMed ID: 18669466
[TBL] [Abstract][Full Text] [Related]
6. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity due to targeted anticancer agents: a growing challenge.
Shah CP; Moreb JS
Ther Adv Cardiovasc Dis; 2019; 13():1753944719843435. PubMed ID: 30995890
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer.
Thuny F; Huttin O; Ederhy S
Arch Cardiovasc Dis; 2019 Oct; 112(10):550-558. PubMed ID: 31522992
[No Abstract] [Full Text] [Related]
9. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
10. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
Robinson EL; Azodi M; Heymans S; Heggermont W
Curr Heart Fail Rep; 2020 Dec; 17(6):357-364. PubMed ID: 32964378
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Cardiotoxicities With Traditional and Novel Chemotherapeutic Agents.
Sharalaya Z; Collier P
Curr Heart Fail Rep; 2018 Aug; 15(4):260-269. PubMed ID: 29938321
[TBL] [Abstract][Full Text] [Related]
13. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
[TBL] [Abstract][Full Text] [Related]
14. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
[TBL] [Abstract][Full Text] [Related]
15. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
Beyer AM; Bonini MG; Moslehi J
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H164-H167. PubMed ID: 31172808
[TBL] [Abstract][Full Text] [Related]
16. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity.
Avila MS; Siqueira SRR; Ferreira SMA; Bocchi EA
Methodist Debakey Cardiovasc J; 2019; 15(4):267-273. PubMed ID: 31988687
[TBL] [Abstract][Full Text] [Related]
17. Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy.
Li H; Mao Y; Zhang Q; Han Q; Man Z; Zhang J; Wang X; Hu R; Zhang X; Irwin DM; Niu G; Tan H
J Ethnopharmacol; 2016 Nov; 192():459-470. PubMed ID: 27586823
[TBL] [Abstract][Full Text] [Related]
18. Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.
Zhu H; Luo P; Fu Y; Wang J; Dai J; Shao J; Yang X; Chang L; Weng Q; Yang B; He Q
Oncotarget; 2015 Feb; 6(5):3254-67. PubMed ID: 25226612
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise.
Wonders KY; Reigle BS
Integr Cancer Ther; 2009 Mar; 8(1):17-21. PubMed ID: 19174506
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
